Actively Recruiting

Age: 19Years - 80Years
All Genders
NCT06153407

Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve

Led by Yonsei University · Updated on 2023-12-01

240

Participants Needed

1

Research Sites

258 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is to elucidate the impact of germline mutations and clonal hematopoiesis (CHIP) on the progression of early aortic valve calcification in patients with bicuspid aortic valves. The study will be conducted over a recruitment period of one year and a follow-up observation period of two years. Considering a 2-year event rate and a 33% occurrence rate of clonal hematopoiesis, each group requires a minimum of 102 participants. Accounting for a 15% dropout rate, a total of 120 participants are needed for each group (type I error (α) = 5%, type II error (β) = 20%). Therefore, the total study population, including patients with normal aortic valve function, is set at 240 participants.

CONDITIONS

Official Title

Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve

Who Can Participate

Age: 19Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with confirmed bicuspid aortic valves based on cardiac imaging (echocardiography, CT, MRI) or surgical findings.
  • Patients aged 20 to 80 years with moderate or greater aortic valve stenosis or regurgitation (early calcification group).
  • Patients aged 20 to 80 years with mild or less aortic valve stenosis or regurgitation (normal valve function group).
  • Patients who understand the study purpose and voluntarily agree to participate.
Not Eligible

You will not qualify if you...

  • Patients with malignant cancers or other serious conditions like stroke that predict survival less than 6 months.
  • Patients without clear confirmation of bicuspid aortic valve.
  • Patients with stage 3 or higher chronic kidney disease.
  • Patients with other inherited heart conditions.
  • Patients with cognitive impairment or unstable heart function who cannot understand the study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine

Seoul, South Korea, 03722

Actively Recruiting

Loading map...

Research Team

I

Iksung Cho

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here